Recursion Pharmaceuticals Inc
Suletud
SektorTervishoid
3.19 1.27
Ülevaade
Aktsiahinna muutus
24h
Min
3.18
Max
3.21
Sissetulek | -14M -131M |
|---|---|
Müük | 1.2M 7.7M |
Aktsiakasum | -0.25 |
Kasumimarginaal | -1,708.018 |
Töötajad | 600 |
EBITDA | -10M -113M |
Järgmine tulemuste avaldamine | 4. nov 2026 |
|---|
Turukapital | 259M 1.9B |
|---|---|
Eelmine avamishind | 1.92 |
Eelmine sulgemishind | 3.19 |
Uudiste sentiment
By Acuity
100%
0%
320 / 339 Pingereas Healthcare
Recursion Pharmaceuticals Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Recursion Pharmaceuticals Inc Prognoos
Sentiment
By Acuity
320 / 339 Pingereas Tervishoid
Uudiste sentiment
Väga tugevad languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.